Gastro

Your Article Summary

See Latest Articles

Surgical outcomes and survival after multiorgan resection for locally advanced gastric cancer
The American Journal of Surgery, 06/24/09

Ozer M et al. - In a trial to evaluate the efficacy of multiple organ resection for locally advanced (assumed T4) gastric cancer with regard to surgical morbidity, mortality, and survival, it was concluded thatmultiple organ resection is worthwhile with careful pt selection.

• 56 pts underwent potentially radical gastrectomy combined with invaded organ resection.
• Early and late results of multiorgan resection and clinicopathologic factors influencing these results were evaluated.

• 40 pts (71.4%) received 1 additional organ resection and 16 pts (28.6%) received 2 or more additional organ resections.
• Postoperative morbidity and mortality was 37.5% and 12.5%, respectively.
• Resection of 2 or more additional organs increased postoperative morbidity and advanced age increased mortality.
• 1- and 3-yr survival rates were 53.3% and 28.1%, respectively.
• Advanced age, lymph node metastasis, and resection of >1 additional organ were significant prognostic factors for survival.

Related Articles

See all related articles

CHD5 is down-regulated through promoter hypermethylation in gastric cancer
BMC: Journal of Biomedical Science, 10/26/09    Relevance Score: 71%

Promoter hypermethylation mediates downregulation of thiamine receptor slc19a3 in gastric cancer
Tumor Biology, 10/12/09    Relevance Score: 71%

KAP1 Is Associated With Peritoneal Carcinomatosis in Gastric Cancer
Annals of Surgical Oncology, 11/11/09    Relevance Score: 69%

Management of patients with pregnancy-associated gastric cancer in Japan: a mini-review
International Journal of Clinical Oncology, 10/30/09    Relevance Score: 69%

A Study of Oxidative Stress Parameters in Anti-Helicobacter Pylorus Immunoglobulin G Positive and Negative Gastric Cancer Patients
Yonsei Medical Journal, 10/29/09    Relevance Score: 69%

Today in GI Oncology...keeping you current

Receive free subspecialty "5-minute updates" via email

A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
Investigational New Drugs, 12/17/09

Delay in Diagnostic Workup and Treatment of Esophageal Cancer
Journal of Gastrointestinal Surgery, 12/17/09

Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours
Alimentary Pharmacology and Therapeutics, 12/17/09

 See all of GI Oncology